- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Patent holdings for IPC class A61K 31/5377
Total number of patents in this class: 12564
10-year publication summary
|
879
|
852
|
814
|
785
|
815
|
797
|
739
|
939
|
1034
|
16
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10534 |
252 |
| Bristol-myers Squibb Company | 4797 |
141 |
| Epizyme, Inc. | 373 |
121 |
| Takeda Pharmaceutical Company Limited | 2713 |
118 |
| Boehringer Ingelheim International GmbH | 4615 |
117 |
| Merck Sharp & Dohme LLC | 3735 |
115 |
| Gilead Sciences, Inc. | 2108 |
113 |
| Merck Patent GmbH | 5733 |
101 |
| F. Hoffmann-La Roche AG | 7898 |
97 |
| Celgene Corporation | 1399 |
97 |
| Taisho Pharmaceutical Co., Ltd. | 866 |
95 |
| Genentech, Inc. | 4005 |
94 |
| Chugai Seiyaku Kabushiki Kaisha | 1386 |
82 |
| Bayer Pharma AG | 1040 |
81 |
| Shionogi & Co., Ltd. | 834 |
81 |
| Dana-Farber Cancer Institute, Inc. | 2619 |
76 |
| Janssen Pharmaceutica N.V. | 3344 |
75 |
| Astellas Pharma Inc. | 1051 |
75 |
| Abbvie Inc. | 1820 |
70 |
| Hoffmann-La Roche Inc. | 3555 |
69 |
| Other owners | 10494 |